PLoS ONE:硫氧还蛋白结合蛋白2增强TGF-β诱导的EMT

2012-07-10 Beyond 生物谷

转化生长因子β(TGF-β)具有调节细胞生长、分化、凋亡、侵袭和各种癌症细胞的上皮间质转化(EMT)等关键作用。TGF-β诱导的EMT是癌细胞侵袭的重要一步。 硫氧还蛋白结合蛋白2 (TBP-2)在多种癌症类型中都表达下调,其表达不足的结果就是促发癌症患者的早期发病。不过,目前还不清楚TBP-2如何抑制癌症的侵袭和转移。PLoS ONE杂志上的一项研究中,科学家证明TBP-2的缺乏增加TGF-β

转化生长因子β(TGF-β)具有调节细胞生长、分化、凋亡、侵袭和各种癌症细胞的上皮间质转化(EMT)等关键作用。TGF-β诱导的EMT是癌细胞侵袭的重要一步。

硫氧还蛋白结合蛋白2 (TBP-2)在多种癌症类型中都表达下调,其表达不足的结果就是促发癌症患者的早期发病。不过,目前还不清楚TBP-2如何抑制癌症的侵袭和转移。PLoS ONE杂志上的一项研究中,科学家证明TBP-2的缺乏增加TGF-β的转录活性,也增强了TGF-β诱导Smad2磷酸化水平的功效。

敲除TBP-2能增强TGF-β调控Snail和Slug的表达,Snail和Slug是介导TGF-β诱导的EMT关键转录因子,TBP-2表达的降低能促进TGF-β诱导的A549细胞纺锤状形态的形成以及降低E-钙粘素的表达。

研究结果表明TBP-2缺失增强TGF-β的信号,促进TGF-β诱导的EMT。抑制TGF-β诱导的EMT对于侵袭和转移的抑制是至关重要的。因此,TBP-2是受TGF-β信号调控的一种新型分子,很可能是一个肿瘤预后指标,是肿瘤治疗的潜在靶标。

doi:10.1371/journal.pone.0039900
PMC:
PMID:

Deficiency of Thioredoxin Binding Protein-2 (TBP-2) Enhances TGF-β Signaling and Promotes Epithelial to Mesenchymal Transition

So Masaki1, Hiroshi Masutani1, Eiji Yoshihara1, Junji Yodoi1,2*

Background

Transforming growth factor beta (TGF-β) has critical roles in regulating cell growth, differentiation, apoptosis, invasion and epithelial-mesenchymal transition (EMT) of various cancer cells. TGF-β-induced EMT is an important step during carcinoma progression to invasion state. Thioredoxin binding protein-2 (TBP-2, also called Txnip or VDUP1) is downregulated in various types of human cancer, and its deficiency results in the earlier onset of cancer. However, it remains unclear how TBP-2 suppresses the invasion and metastasis of cancer.

Principal Findings

In this study, we demonstrated that TBP-2 deficiency increases the transcriptional activity in response to TGF-β and also enhances TGF-β-induced Smad2 phosphorylation levels. Knockdown of TBP-2 augmented the TGF-β-responsive expression of Snail and Slug, transcriptional factors related to TGF-β-mediated induction of EMT, and promoted TGF-β-induced spindle-like morphology consistent with the depletion of E-Cadherin in A549 cells.

Conclusions/Significance

Our results indicate that TBP-2 deficiency enhances TGF-β signaling and promotes TGF-β-induced EMT. The control of TGF-β-induced EMT is critical for the inhibition of the invasion and metastasis. Thus TBP-2, as a novel regulatory molecule of TGF-β signaling, is likely to be a prognostic indicator or a potential therapeutic target for preventing tumor progression.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2070892, encodeId=6d7920e089208, content=<a href='/topic/show?id=d686e35628b' target=_blank style='color:#2F92EE;'>#硫氧还蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73562, encryptionId=d686e35628b, topicName=硫氧还蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Oct 19 05:07:00 CST 2012, time=2012-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035835, encodeId=2133203583565, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Sun Apr 21 07:07:00 CST 2013, time=2013-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801369, encodeId=6a4d180136934, content=<a href='/topic/show?id=ac32e356419' target=_blank style='color:#2F92EE;'>#硫氧还蛋白结合蛋白2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73564, encryptionId=ac32e356419, topicName=硫氧还蛋白结合蛋白2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Mon May 13 00:07:00 CST 2013, time=2013-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789452, encodeId=051f1e8945298, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Jan 28 14:07:00 CST 2013, time=2013-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441347, encodeId=af50144134e5d, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=496f4824495, createdName=ms6980045490879608, createdTime=Thu Jul 12 06:07:00 CST 2012, time=2012-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462115, encodeId=9f2d146211500, content=<a href='/topic/show?id=c6436e385a' target=_blank style='color:#2F92EE;'>#EMT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6738, encryptionId=c6436e385a, topicName=EMT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f216475172, createdName=lfcmxl, createdTime=Thu Jul 12 06:07:00 CST 2012, time=2012-07-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2070892, encodeId=6d7920e089208, content=<a href='/topic/show?id=d686e35628b' target=_blank style='color:#2F92EE;'>#硫氧还蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73562, encryptionId=d686e35628b, topicName=硫氧还蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Oct 19 05:07:00 CST 2012, time=2012-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035835, encodeId=2133203583565, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Sun Apr 21 07:07:00 CST 2013, time=2013-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801369, encodeId=6a4d180136934, content=<a href='/topic/show?id=ac32e356419' target=_blank style='color:#2F92EE;'>#硫氧还蛋白结合蛋白2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73564, encryptionId=ac32e356419, topicName=硫氧还蛋白结合蛋白2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Mon May 13 00:07:00 CST 2013, time=2013-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789452, encodeId=051f1e8945298, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Jan 28 14:07:00 CST 2013, time=2013-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441347, encodeId=af50144134e5d, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=496f4824495, createdName=ms6980045490879608, createdTime=Thu Jul 12 06:07:00 CST 2012, time=2012-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462115, encodeId=9f2d146211500, content=<a href='/topic/show?id=c6436e385a' target=_blank style='color:#2F92EE;'>#EMT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6738, encryptionId=c6436e385a, topicName=EMT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f216475172, createdName=lfcmxl, createdTime=Thu Jul 12 06:07:00 CST 2012, time=2012-07-12, status=1, ipAttribution=)]
    2013-04-21 changhe713
  3. [GetPortalCommentsPageByObjectIdResponse(id=2070892, encodeId=6d7920e089208, content=<a href='/topic/show?id=d686e35628b' target=_blank style='color:#2F92EE;'>#硫氧还蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73562, encryptionId=d686e35628b, topicName=硫氧还蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Oct 19 05:07:00 CST 2012, time=2012-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035835, encodeId=2133203583565, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Sun Apr 21 07:07:00 CST 2013, time=2013-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801369, encodeId=6a4d180136934, content=<a href='/topic/show?id=ac32e356419' target=_blank style='color:#2F92EE;'>#硫氧还蛋白结合蛋白2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73564, encryptionId=ac32e356419, topicName=硫氧还蛋白结合蛋白2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Mon May 13 00:07:00 CST 2013, time=2013-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789452, encodeId=051f1e8945298, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Jan 28 14:07:00 CST 2013, time=2013-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441347, encodeId=af50144134e5d, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=496f4824495, createdName=ms6980045490879608, createdTime=Thu Jul 12 06:07:00 CST 2012, time=2012-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462115, encodeId=9f2d146211500, content=<a href='/topic/show?id=c6436e385a' target=_blank style='color:#2F92EE;'>#EMT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6738, encryptionId=c6436e385a, topicName=EMT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f216475172, createdName=lfcmxl, createdTime=Thu Jul 12 06:07:00 CST 2012, time=2012-07-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2070892, encodeId=6d7920e089208, content=<a href='/topic/show?id=d686e35628b' target=_blank style='color:#2F92EE;'>#硫氧还蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73562, encryptionId=d686e35628b, topicName=硫氧还蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Oct 19 05:07:00 CST 2012, time=2012-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035835, encodeId=2133203583565, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Sun Apr 21 07:07:00 CST 2013, time=2013-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801369, encodeId=6a4d180136934, content=<a href='/topic/show?id=ac32e356419' target=_blank style='color:#2F92EE;'>#硫氧还蛋白结合蛋白2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73564, encryptionId=ac32e356419, topicName=硫氧还蛋白结合蛋白2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Mon May 13 00:07:00 CST 2013, time=2013-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789452, encodeId=051f1e8945298, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Jan 28 14:07:00 CST 2013, time=2013-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441347, encodeId=af50144134e5d, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=496f4824495, createdName=ms6980045490879608, createdTime=Thu Jul 12 06:07:00 CST 2012, time=2012-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462115, encodeId=9f2d146211500, content=<a href='/topic/show?id=c6436e385a' target=_blank style='color:#2F92EE;'>#EMT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6738, encryptionId=c6436e385a, topicName=EMT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f216475172, createdName=lfcmxl, createdTime=Thu Jul 12 06:07:00 CST 2012, time=2012-07-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2070892, encodeId=6d7920e089208, content=<a href='/topic/show?id=d686e35628b' target=_blank style='color:#2F92EE;'>#硫氧还蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73562, encryptionId=d686e35628b, topicName=硫氧还蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Oct 19 05:07:00 CST 2012, time=2012-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035835, encodeId=2133203583565, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Sun Apr 21 07:07:00 CST 2013, time=2013-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801369, encodeId=6a4d180136934, content=<a href='/topic/show?id=ac32e356419' target=_blank style='color:#2F92EE;'>#硫氧还蛋白结合蛋白2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73564, encryptionId=ac32e356419, topicName=硫氧还蛋白结合蛋白2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Mon May 13 00:07:00 CST 2013, time=2013-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789452, encodeId=051f1e8945298, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Jan 28 14:07:00 CST 2013, time=2013-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441347, encodeId=af50144134e5d, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=496f4824495, createdName=ms6980045490879608, createdTime=Thu Jul 12 06:07:00 CST 2012, time=2012-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462115, encodeId=9f2d146211500, content=<a href='/topic/show?id=c6436e385a' target=_blank style='color:#2F92EE;'>#EMT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6738, encryptionId=c6436e385a, topicName=EMT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f216475172, createdName=lfcmxl, createdTime=Thu Jul 12 06:07:00 CST 2012, time=2012-07-12, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2070892, encodeId=6d7920e089208, content=<a href='/topic/show?id=d686e35628b' target=_blank style='color:#2F92EE;'>#硫氧还蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73562, encryptionId=d686e35628b, topicName=硫氧还蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Oct 19 05:07:00 CST 2012, time=2012-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035835, encodeId=2133203583565, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Sun Apr 21 07:07:00 CST 2013, time=2013-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801369, encodeId=6a4d180136934, content=<a href='/topic/show?id=ac32e356419' target=_blank style='color:#2F92EE;'>#硫氧还蛋白结合蛋白2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73564, encryptionId=ac32e356419, topicName=硫氧还蛋白结合蛋白2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Mon May 13 00:07:00 CST 2013, time=2013-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789452, encodeId=051f1e8945298, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Jan 28 14:07:00 CST 2013, time=2013-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441347, encodeId=af50144134e5d, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=496f4824495, createdName=ms6980045490879608, createdTime=Thu Jul 12 06:07:00 CST 2012, time=2012-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462115, encodeId=9f2d146211500, content=<a href='/topic/show?id=c6436e385a' target=_blank style='color:#2F92EE;'>#EMT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6738, encryptionId=c6436e385a, topicName=EMT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f216475172, createdName=lfcmxl, createdTime=Thu Jul 12 06:07:00 CST 2012, time=2012-07-12, status=1, ipAttribution=)]
    2012-07-12 lfcmxl

相关资讯

PLoS ONE:多国科学家携手研究抗结核病新药

结核病是一种古老的疾病,其致死病例可以追溯到公元前3世纪,而目前每年还有大约140万人死于结核病。 结核分枝杆菌是结核病的病原体,常规化学药物治疗至少耗时6个月,且耐药现象日益严重。二氢叶酸还原酶催化产生的四氢叶酸是合成嘌呤和胸腺嘧啶的重要底物,抑制该酶的活性可以阻断DNA和RNA的合成,从而杀灭病原菌。 在世界卫生组织的支持下,中国、印度、肯尼亚、尼日利亚和美国的科研人员紧密合作,通过对

PLoS One:双氢青蒿素诱导肝癌细胞凋亡

肝癌患病率和死亡率是所有癌症中的前五位,科研界也一直关注于开发治疗肝癌的新策略。青蒿素(artemisinin)是我国科研人员率先从“黄花蒿”中分离提取得到的一种高效低毒抗疟药物。青蒿素内含有独特的过氧化物桥,可以与亚铁离子结合反应形成氧自由基,诱导细胞发生分子损伤和细胞死亡,或通过直接氧化作用损伤细胞的结构和功能,从而导致细胞死亡。 双氢青蒿素(dihydroartemisinin,DHA)是

PLoS One:黄酮类物质抑制前列腺癌生长和转移

黄酮类化合物(flavonoids)是一类存在于自然界的、具有2-苯基色原酮(flavone)结构的化合物。黄酮类化合物在植物体中通常与糖结合成苷类,小部分以游离态(苷元)的形式存在。绝大多数植物体内都含有黄酮类化合物,它在植物的生长、发育、开花、结果以及抗菌防病等方起着重要的作用。 近年来,黄酮类化合物的抗肿瘤机制逐步得到研究人员重视,如槲皮素的抗肿瘤活性与其抗氧化作用、抑制相关酶的活性、降低

PLoS One:小窝蛋白1促进肿瘤侵袭转移

胞膜小窝(caveolae)是细胞质膜内陷所形成的囊状结构.小窝蛋白(caveolin)是胞膜小窝区别于其它脂筏结构的特征性蛋白分子,维持胞膜小窝的结构和功能,包括3个家族成员小窝蛋白-1、小窝蛋白-2和小窝蛋白-3。其中,小窝蛋白-1是参与胆固醇平衡、分子运输和跨膜信号发放事件的主要结构成分,从而调节细胞的生长、发育和增殖。 小窝蛋白1(Caveolin-1)有促进细胞迁移的作用,Caveol

PLoS ONE:间充质干细胞保护移植的胰岛免受炎症作用

近日,来自加拿大阿尔伯塔大学的研究人员发现,人间充质干细胞(MSCs)能够保护胰岛免受促炎性细胞因子的损害,因此在胰岛移植中可能扮演了重要的保护作用。相关研究成果于5月30日在线发表在PLoS ONE上。 1型糖尿病患者为了维持身体健康每天都需要注射胰岛素,则一劳永逸的胰岛移植是一个不错的选择。然而,大多数胰岛移植受体在五年内都失去了胰岛的正常功能。研究发现,炎症是移植失败一个主要的促进因素,而

PLoS ONE:阻断FGFR抑制肿瘤转移

成纤维细胞生长因子受体(FGFR)对肿瘤的生长和癌症病人的生存起着至关重要的作用。相比于其他受体酪氨酸激酶,科学家也一直将成纤维细胞生长因子(成纤维细胞生长因子)作为一种治疗癌症的靶标来开展研究。 近日,研究发现FGFR信号抑制后对原位乳腺66c14癌模型肿瘤生长、转移和淋巴血管形成的影响。体外研究表明FGFR抑制后,66c14细胞增殖比对照组慢。小鼠植入FGFR表达抑制的肿瘤细胞后,66c14